Literature DB >> 21531014

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.

Linda Cox, Phillip Lieberman, Dana Wallace, F Estelle R Simons, Ira Finegold, Thomas Platts-Mills, Lawrence Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21531014     DOI： 10.1016/j.jaci.2011.04.010

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  25 in total

1.  Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria.

Authors:  Eric Tyrell Oliver; Kris Chichester; Kelly Devine; Patricia Meghan Sterba; Craig Wegner; Becky Marie Vonakis; Sarbjit Singh Saini
Journal:  Int Arch Allergy Immunol       Date:  2019-03-15       Impact factor: 2.749

2.  [Undesired cutaneous adverse drug reactions: What is new?].

Authors:  R Treudler; J C Simon
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 3.  Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?

Authors:  Hengameh H Raissy; H William Kelly
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

Review 4.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

Review 5.  Biologics in asthma--the next step toward personalized treatment.

Authors:  Jared Darveaux; William W Busse
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

Review 6.  Use of omalizumab in the treatment of food allergy and anaphylaxis.

Authors:  Jay A Lieberman; Mirna Chehade
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 7.  Contemporary Pharmacotherapy for Allergic Rhinitis and Chronic Rhinosinusitis.

Authors:  Saied Ghadersohi; Bruce K Tan
Journal:  Otolaryngol Clin North Am       Date:  2017-09-28       Impact factor: 3.346

8.  Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.

Authors:  Alexander Eggel; Günther Baravalle; Gabriel Hobi; Beomkyu Kim; Patrick Buschor; Patrik Forrer; Jeoung-Sook Shin; Monique Vogel; Beda M Stadler; Clemens A Dahinden; Theodore S Jardetzky
Journal:  J Allergy Clin Immunol       Date:  2014-03-15       Impact factor: 10.793

9.  Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.

Authors:  Lisha Li; Zixi Wang; Le Cui; Yingyang Xu; Kai Guan; Bin Zhao
Journal:  Clin Transl Allergy       Date:  2021-06-03       Impact factor: 5.871

Review 10.  Hypersensitivity and Immune-related Adverse Events in Biologic Therapy.

Authors:  Jamie L Waldron; Stephen A Schworer; Mildred Kwan
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-28       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.